The Challenge to the Pathologist of PD-L1 Expression in Tumor Cells of Non-Small-Cell Lung Cancer—An Overview

In recent years, the treatment of non-small-cell lung cancer (NSCLC) has been fundamentally changed by immunotherapy where the immune system is reactivated using anti-programmed cell death protein 1/programmed death ligand 1 (PD1/PD-L1) checkpoint inhibition. With this, the immunohistological detect...

Descripción completa

Detalles Bibliográficos
Autores principales: Jöhrens, Korinna, Rüschoff, Josef
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8699902/
https://www.ncbi.nlm.nih.gov/pubmed/34940076
http://dx.doi.org/10.3390/curroncol28060437

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8699902/
https://www.ncbi.nlm.nih.gov/pubmed/34940076
http://dx.doi.org/10.3390/curroncol28060437

Ejemplares similares